FDA Cuts Sample Size in Narcolepsy Trial, AVDL Stock Goes Flying

AVDL stock

It’s only Monday, but Avadel Pharmaceuticals (NASDAQ:AVDL) is already making headlines. AVDL stock is soaring after the pharmaceutical company said the FDA cut its sample size in one of its trials.

Here’s everything we know.

AVDL Stock Goes Flying: The Details

On September 23, Avadel Pharmaceuticals, an Ireland-based company, said the FDA agreed to cut the sample size in its phase 3 trial of narcolepsy treatment. Instead of 264 patients, the trial will target 205 narcolepsy patients. According to the report, no modifications were made to the design of the study, which means the ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.